{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:17:03Z","timestamp":1786119423010,"version":"build-2736575974"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1097\/yco.0b013e3283386578","type":"journal-article","created":{"date-parts":[[2010,3,25]],"date-time":"2010-03-25T02:31:19Z","timestamp":1269484279000},"page":"210-214","source":"Crossref","is-referenced-by-count":52,"title":["Long-acting depot formulations of naltrexone for heroin dependence: a review"],"prefix":"10.1097","volume":"23","author":[{"given":"Evgeny M","family":"Krupitsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena A","family":"Blokhina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210206","doi-asserted-by":"crossref","first-page":"455","DOI":"10.31887\/DCNS.2007.9.4\/hkleber","article-title":"Pharmacologic treatments for opioid dependence: detoxification and maintenance options","volume":"9","author":"Kleber","year":"2007","journal-title":"Dialogues Clin Neurosci"},{"key":"R2-5-20210206","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jsat.2006.05.005","article-title":"Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia","volume":"31","author":"Krupitsky","year":"2006","journal-title":"J Subst Abuse Treat"},{"key":"R3-5-20210206","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2217\/14796708.1.4.389","article-title":"Sustained-release naltrexone formulations for the treatment of alcohol and opioid dependence","volume":"1","author":"Volpicelli","year":"2006","journal-title":"Future Neurol"},{"key":"R4-5-20210206","doi-asserted-by":"crossref","first-page":"862","DOI":"10.15288\/jsad.2007.68.862","article-title":"Population pharmacokinetics of extended-release injectable naltrexone (XR-NTX) in patients with alcohol dependence","volume":"68","author":"Dunbar","year":"2007","journal-title":"J Stud Alcohol Drugs"},{"key":"R5-5-20210206","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/archpsyc.63.2.210","article-title":"Injectable, sustained-release naltrexone for the treatment of opioid dependence","volume":"63","author":"Comer","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"R6-5-20210206","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1530-0277.2006.00052.x","article-title":"Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone","volume":"30","author":"Dunbar","year":"2006","journal-title":"Alcohol Clin Exp Res"},{"key":"R7-5-20210206","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1111\/j.1360-0443.2008.02252.x","article-title":"Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone","volume":"103","author":"Fishman","year":"2008","journal-title":"Addiction"},{"key":"R8-5-20210206","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1111\/j.1360-0443.2007.01817.x","article-title":"Overcoming opioid blockade from depot naltrexone (Prodetoxon\u00ae)","volume":"102","author":"Kruptisky","year":"2007","journal-title":"Addiction"},{"issue":"1\u20132","key":"R9-5-20210206","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijpharm.2007.03.033","article-title":"A \u2018biorelevant\u2019 approach to accelerated in vitro drug release testing of a biodegradable, naltrexone implant","volume":"340","author":"Iyer","year":"2007","journal-title":"Int J Pharm"},{"issue":"1\u20132","key":"R10-5-20210206","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijpharm.2007.03.032","article-title":"A \u2018biorelevant\u2019 system to investigate in vitro drug released from a naltrexone implant","volume":"340","author":"Iyer","year":"2007","journal-title":"Int J Pharm"},{"key":"R11-5-20210206","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pnpbp.2007.06.007","article-title":"Blood naltrexone levels over time following naltrexone implant","volume":"32","author":"Ngo","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R14-5-20210206","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1747-597X-2-35","article-title":"Psychosocial and treatment correlates of opiate free success in a clinical review of a naltrexone implant program","volume":"2","author":"Reece","year":"2007","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"R15-5-20210206","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/archgenpsychiatry.2009.130","article-title":"Improving clinical outcomes in treating heroin dependence","volume":"66","author":"Hulse","year":"2009","journal-title":"Arch Gen Psychiatry"},{"key":"R16-5-20210206","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1192\/bjp.bp.108.055319","article-title":"Naltrexone implants after in-patient treatment for opioid dependence: randomized controlled trial","volume":"194","author":"Kunoe","year":"2009","journal-title":"Br J Psychiatry"},{"key":"R17-5-20210206","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0924-977X(09)70234-2","article-title":"Long acting naltrexone implants for heroin dependence","volume":"19","author":"Krupitsky","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"key":"R18-5-20210206","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jsat.2009.03.008","article-title":"Comparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphine.","volume":"37","author":"Reece","year":"2009","journal-title":"J Subst Abuse Treat"},{"key":"R19-5-20210206","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1001\/archpsyc.65.4.457","article-title":"Comparing drug-related hospital morbidity following heroin dependence treatment with methadone maintenance therapy or naltrexone implantation","volume":"65","author":"Ngo","year":"2008","journal-title":"Arch Gen Psychiatry"},{"key":"R20-5-20210206","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jsat.2007.08.014","article-title":"Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment","volume":"35","author":"Tait","year":"2008","journal-title":"J Subst Abuse Treat"},{"key":"R21-5-20210206","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09595230701711157","article-title":"Depot naltrexone use for opioid dependence in Australia: large-scale use of an unregistered medication in the absence of data on safety and efficacy","volume":"27","author":"Degenhardt","year":"2008","journal-title":"Drug Alcohol Rev"}],"container-title":["Current Opinion in Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/YCO.0b013e3283386578","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:13:27Z","timestamp":1786040007000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001504-201005000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/yco.0b013e3283386578","relation":{},"ISSN":["0951-7367"],"issn-type":[{"value":"0951-7367","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}